Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1353 • ACR Convergence 2023
Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Maria Helena Lourenco¹, Rita Torres², Santiago Rodrigues-Manica³, Vanessa Fraga⁴, Ana Catarina Abreu⁵, Roberto Costa⁶, Carolina Ochôa Matos⁷, Beatriz Mendes⁸, Beatriz Samões⁹, Inês Silva¹, Fernando Pimentel-Santos¹⁰, Manuela Costa¹, Jaime Branco¹¹ and Alexandre Sepriano¹², ¹Hospital Egas Moniz, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal, ³Hospital Egas Moniz, CHLO, Lisboa, Portugal, ⁴Hospital Garcia de Orta, Nogueira da Regedoura, Portugal, ⁵Hospital Garcia de Orta, Lisboa, Portugal, ⁶Centro Hospitalar Lisboa Norte, Lisboa, Portugal, ⁷Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁸Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁹Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal, ¹⁰NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ¹¹CHLO, EPE - Hospital Egas Moniz, Lisbon, Portugal, ¹²Leiden University Medical Centre, Portela Loures, Portugal
Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a…
Abstract Number: 1451 • ACR Convergence 2023
Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
Micaela Fredi¹, Silvia Ebe Lucia Della Pina¹, Claudia Barison¹, Chiara Orlandi¹, Marzia Tedeschi², Mai Chiara², Cecilia Nalli¹ and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²University of Brescia, Brescia, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a high degree of variability at onset, which may make SLE diagnosis challenging, with…
Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Hsin Yen Liu¹, Jiandong Su², Dennisse Bonilla², Sara Duaibes², Juan Pablo Diaz Martinez³ and Zahi Touma¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…
Abstract Number: 1485 • ACR Convergence 2023
Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco² and Socorro Méndez Martínez¹, ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE…
Abstract Number: 1502 • ACR Convergence 2023
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Kanako Kojima¹, Kunihiro Ichinose¹, Toshimasa Shimizu¹, Masataka Umeda¹, Takahisa Suzuki², Yoshikazu Nakashima³, Akitomo Okada⁴, Yoshiro Horai⁵, Keita Fujikawa⁶, Toshiyuki Aramaki⁷, Taiichiro Miyashita⁸, Masako Furuyama³, Naoki Matsuoka⁹ and Atsushi Kawakami¹⁰, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ³Nagasaki Kita Hospital, Nagasaki, Japan, ⁴National Hospital Organization Nagasaki Medical Center, Omura, Japan, ⁵Sasebo City General Hospital, Sasebo, Japan, ⁶Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, ⁷Sasebo Chuo Hospital, Sasebo, Japan, ⁸Miyashita Rheumatology Clinic, Omura, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Nagasaki University, Nagasaki, Japan
Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…
Abstract Number: 1599 • ACR Convergence 2023
Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus
Mitra Maz¹, Feiyang Ma², Mehrnaz Gharaee-Kermani², Amanda Victory², Amy Hurst², Johann E. Gudjonsson² and J. Michelle Kahlenberg², ¹University of Michigan Medical School, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 2030 • ACR Convergence 2023
Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History
Kimberly DeQuattro¹, Laura Trupin², Sarah Patterson³, Stephanie Rush², Caroline Gordon⁴, Kurt Greenlund⁵, Kamil Barbour⁵, Cristina Lanata⁶, Lindsey Criswell⁷, Maria Dall'Era², Jinoos Yazdany² and Patti Katz⁸, ¹University of Pennsylvania, Media, PA, ²University of California San Francisco, San Francisco, CA, ³University of California San Francisco, Pacifica, CA, ⁴Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Centers for Disease Control and Prevention, Atlanta, GA, ⁶National Human Genome Research Institute, Washington, DC, ⁷NIH/NHGRI, Bethesda, MD, ⁸University of California San Francisco, San Rafael, CA
Background/Purpose: Trauma exposures are associated with SLE onset and disease activity; perceived stress is also associated with greater SLE disease activity and worse patient-reported outcomes.…
Abstract Number: 2267 • ACR Convergence 2023
Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus
Hsin-Hua Chen¹ and Wen-Nan Huang², ¹Taichung Veterans General Hospital, Taichung, Taiwan, ²Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Veterans General Hospital, College of Medicine National Chung Hsing University, Department of Business Administration, Ling-Tung University, Taichung, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 1.85-fold higher risk of all-cause mortality and a 2.74 fold higher risk of infection-related mortality compared…
Abstract Number: 2284 • ACR Convergence 2023
Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea
Ji-Hyoun Kang¹, Hyemin Jeong², Sung-Eun Choi², Dong-Jin Park², Han Joo Baek³, Hyo-Jin Choi⁴, Jae Hyun Jung⁵ and Shin-Seok Lee², ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Gil Medical Center, Gachon University College of Medicine, Inchon, South Korea, ⁴Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea, ⁵Korea University Ansan Hospital, Ansan-si, South Korea
Background/Purpose: Exposure to air pollutants is associated with an increased risk of pulmonary and cardiovascular disease and death. Because few studies have investigated the effects…
Abstract Number: 2301 • ACR Convergence 2023
Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years
Shuzo Sato¹, Shuhei Yoshida¹, Yuya Sumichika¹, Kenji Saito¹, Haruki Matsumoto¹, Jumpei Temmoku¹, Yuya Fujita¹, Naoki Matsuoka¹, Tomoyuki Asano¹ and KIYOSHI MIGITA², ¹Fukushima Medical University, Fukushima, Japan, ²Department of Rheumatology Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: SLE patients often experience relapse in the course of treatment, in spite of the progress of therapeutic strategy in SLE. The purpose of this…
Abstract Number: 2317 • ACR Convergence 2023
Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study
Fung Lam¹, Chi Hung To¹ and Chi Chiu Mok², ¹Pok Oi Hospital, Hong Kong, Hong Kong, ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: The SLE Disease Activity Score (SLE-DAS) has been developed and validated in Italian patients with SLE. The objective of this study was to evaluate…
Abstract Number: 2334 • ACR Convergence 2023
Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period
Ronald van Vollenhoven¹, Eric Morand², Richard A. Furie³, Kenneth Kalunian⁴, Raj Tummala⁵, Gabriel Abreu⁶, Hussein Al-Mossawi⁷ and Catharina Lindholm⁶, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴University of California San Diego, La Jolla, CA, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: In patients with SLE, remission is an established therapeutic goal associated with reduced damage accrual and flares, and improved health-related quality of life.1 Here,…
Abstract Number: 2443 • ACR Convergence 2023
Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus
Junpeng Zhao¹, Liming Li¹, Xiwei Feng¹, Huiqi Yin¹ and Qianjin Lu², ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China, ²Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Changsha, China
Background/Purpose: Genetic variations in the OX40 ligand (OX40L) locus have been implicated in the susceptibility to systemic lupus erythematosus (SLE). Notably, the blockade of OX40L…
Abstract Number: 2490 • ACR Convergence 2023
Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
Junna Ye¹, Yijun You², Zhuochao Zhou², Jingyi Wu², Fan wang² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Previous clinical trials of mycophenolate mofetil (MMF) in SLE were mainly focused on lupus nephritis (LN) (patients have been diagnosed with LN). In the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].